CTXR Citius Pharmaceuticals, Inc.Financial Income Statement
$0.65-0.02 (-2.86%)4:00 PM 05/17/24
NASDAQ | $USD | Post-Market: $0.66 +0.01 (+1.77%) 7:47 PM
CTXR Income Statement
Period
View
Order
Currency
Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | ||||||||||||
| Other Revenues | - | - | - | - | - | - | ||||||
Operating Expenses & Income | ||||||||||||
| Selling General & Admin Expenses | 7.0 | 8.9 | 11.3 | 15.7 | 21.9 | 26.2 | ||||||
| R&D Expenses | 8.6 | 8.8 | 12.2 | 17.7 | 14.8 | 12.9 | ||||||
| Total Operating Expenses | 15.6 | 17.7 | 23.5 | 33.3 | 36.7 | 39.1 | ||||||
| Operating Income | (15.6) | (17.7) | (23.5) | (33.3) | (36.7) | (39.1) | ||||||
Earnings from Continuing Operations | ||||||||||||
| Interest Expense | (0.0) | (0.0) | (0.0) | - | - | - | ||||||
| Interest And Investment Income | 0.1 | 0.1 | 0.3 | 0.3 | 1.2 | 1.1 | ||||||
| Net Interest Expenses | 0.0 | 0.1 | 0.3 | 0.3 | 1.2 | 1.1 | ||||||
| Other Non Operating Income (Expenses) | - | 0.1 | - | - | - | - | ||||||
| EBT, Incl. Unusual Items | (15.6) | (17.5) | (23.1) | (33.1) | (32.0) | (35.6) | ||||||
| Income Tax Expense | - | - | - | 0.6 | 0.6 | 0.6 | ||||||
| Earnings From Continuing Operations | (15.6) | (17.5) | (23.1) | (33.6) | (32.5) | (36.2) | ||||||
Net Income | ||||||||||||
| Net Income to Company | (15.6) | (17.5) | (23.1) | (33.6) | (32.5) | (36.2) | ||||||
| Net Income | (15.6) | (17.5) | (23.1) | (33.6) | (32.5) | (36.2) | ||||||
| Preferred Dividend and Other Adjustments | - | - | 1.5 | - | 1.2 | 1.2 | ||||||
| NI to Common Incl Extra Items | (15.6) | (17.5) | (24.5) | (33.6) | (33.7) | (37.3) | ||||||
| NI to Common Excl. Extra Items | (15.6) | (17.5) | (24.5) | (33.6) | (33.7) | (37.3) | ||||||
Supplemental Items | ||||||||||||
| Basic EPS | ($0.77) | ($0.45) | ($0.23) | ($0.23) | ($0.22) | ($0.24) | ||||||
| Basic EPS - Continuing Ops | ($0.77) | ($0.45) | ($0.23) | ($0.23) | ($0.22) | ($0.24) | ||||||
| Basic Weighted Average Shares Outst. | 20.2 | 39.2 | 108.6 | 146.1 | 151.3 | 157.7 | ||||||
| Diluted EPS | ($0.77) | ($0.45) | ($0.23) | ($0.23) | ($0.22) | ($0.24) | ||||||
| Diluted EPS - Continuing Ops | ($0.77) | ($0.45) | ($0.23) | ($0.23) | ($0.22) | ($0.24) | ||||||
| Diluted Weighted Average Shares Outst. | 20.2 | 39.2 | 108.6 | 146.1 | 151.3 | 157.7 | ||||||
| Normalized Basic EPS | ($0.48) | ($0.28) | ($0.13) | ($0.14) | ($0.15) | ($0.15) | ||||||
| Normalized Diluted EPS | ($0.48) | ($0.28) | ($0.13) | ($0.14) | ($0.15) | ($0.15) | ||||||
| EBITDA | (15.6) | (17.7) | (23.5) | (33.3) | (36.7) | (39.1) | ||||||
| EBITA | (15.6) | (17.7) | (23.5) | (33.3) | (36.7) | (39.1) | ||||||
| EBIT | (15.6) | (17.7) | (23.5) | (33.3) | (36.7) | (39.1) | ||||||
| EBITDAR | - | (17.5) | (23.3) | (33.1) | (36.5) | - | ||||||
| Effective Tax Rate | - | - | - | NM | NM | NM | ||||||
| Normalized Net Income | (9.7) | (11.0) | (14.6) | (20.7) | (22.2) | (23.8) | ||||||
| Interest on Long-Term Debt | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | - | ||||||
| R&D Expense From Footnotes | 8.6 | 8.8 | 12.2 | 17.7 | 14.8 | 12.9 | ||||||
In Millions of United States Dollar (USD) except per share items